Stocktoria

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB

Nasdaq · stock · Laboratory Analytical Instruments · website · IPO 2010-10-27 · LEI

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $160.0M at a -341.5% net margin.

Chart by TradingView
24/100
Stocktoria Quality Score · grade D
3/9
Piotroski F — financial health
-13.42
Altman Z″ — distress risk · distress
Dividend yield · no dividend

Quality score trend · recomputed for each fiscal year

Piotroski F /9
2 3 4 4 5 3 2 4 2 3 2016201720182019202020212022202320242025
Altman Z″
-16.84 -19.21 -16.62 -0.35 1.36 -1.32 -1.59 -5.15 -13.42 2016201720182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$1.11 as of 2026-08-12 · -13.3% 1y
$1.11$2.3452-wk
Market cap USD$512M
Net margin 5y avg-215.9%
Return on equity 5y avg-2079.6%
Beta2.32
Employees485

Analyst price target

$2.46 +121.5% vs last
consensus: buy · 6 analysts
target range $1.50 – $3.00

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Smart money · insiders, last 12 months

Insiders net sold -$120,813 on the open market · 1 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 10y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 27%
Net marginstronger than 15%
Return on equitystronger than 0%
Revenue growthstronger than 47%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 3/9 tests passed

Altman Z″ components · distress zone

ComponentValue
Working capital / assets0.385
Retained earnings / assets-3.438
EBIT / assets-0.706
Equity / liabilities0.007

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC.3/9-13.42+3.9%
QTRXQuanterix Corp1/9-1.83+1.1%
CTKBCytek Biosciences, Inc.3/96.15+0.5%
HBIOHARVARD BIOSCIENCE INC4/9-10.45-8.1%
PRPOPrecipio, Inc.7/9-13.13+28%
RPIDRAPID MICRO BIOSYSTEMS, INC.2/9+19.7%
EYPTEyePoint, Inc.1/9-3.58-27.5%

All Manufacturing companies →

About PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

FAQ

Is PACB financially healthy?

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.

Does PACB pay a dividend?

No, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. does not currently pay a dividend.

How profitable is PACB?

In FY2025, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. had a net margin of -341.5% and a return on equity of -10214.5%.

What is the analyst price target for PACB?

The average Wall-Street price target for PACIFIC BIOSCIENCES OF CALIFORNIA, INC. is $2.46, about 121.5% above the recent price, from 6 analysts (consensus: buy).

Is PACB a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.